Dianthus Therapeutics (NASDAQ:DNTH) Sets New 12-Month Low – Here’s Why

Dianthus Therapeutics, Inc. (NASDAQ:DNTH)’s stock price reached a new 52-week low during trading on Tuesday . The company traded as low as $18.13 and last traded at $19.17, with a volume of 28891 shares traded. The stock had previously closed at $19.62.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. Raymond James raised Dianthus Therapeutics to a “moderate buy” rating in a research note on Thursday, December 12th. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 target price on shares of Dianthus Therapeutics in a research report on Monday, November 11th. TD Cowen began coverage on shares of Dianthus Therapeutics in a research report on Friday, December 20th. They set a “buy” rating on the stock. Finally, Oppenheimer raised their price objective on shares of Dianthus Therapeutics from $48.00 to $52.00 and gave the company an “outperform” rating in a research note on Monday, November 11th. Seven research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, Dianthus Therapeutics currently has an average rating of “Buy” and a consensus target price of $46.83.

Dianthus Therapeutics Price Performance

The company has a market capitalization of $587.32 million, a price-to-earnings ratio of -7.91 and a beta of 1.72. The stock has a 50 day simple moving average of $22.59 and a two-hundred day simple moving average of $25.20.

Institutional Investors Weigh In On Dianthus Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Woodline Partners LP boosted its holdings in Dianthus Therapeutics by 20.0% in the fourth quarter. Woodline Partners LP now owns 300,504 shares of the company’s stock valued at $6,551,000 after purchasing an additional 50,000 shares in the last quarter. Vestal Point Capital LP grew its position in shares of Dianthus Therapeutics by 172.2% in the 4th quarter. Vestal Point Capital LP now owns 1,075,000 shares of the company’s stock valued at $23,435,000 after buying an additional 680,000 shares during the last quarter. Octagon Capital Advisors LP grew its position in shares of Dianthus Therapeutics by 20.8% in the 4th quarter. Octagon Capital Advisors LP now owns 2,110,167 shares of the company’s stock valued at $46,002,000 after buying an additional 363,500 shares during the last quarter. Millennium Management LLC raised its stake in Dianthus Therapeutics by 160.2% during the 4th quarter. Millennium Management LLC now owns 90,436 shares of the company’s stock worth $1,972,000 after acquiring an additional 55,682 shares in the last quarter. Finally, Janus Henderson Group PLC lifted its position in Dianthus Therapeutics by 14.4% in the fourth quarter. Janus Henderson Group PLC now owns 1,085,648 shares of the company’s stock valued at $23,607,000 after acquiring an additional 136,314 shares during the last quarter. Institutional investors and hedge funds own 47.53% of the company’s stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.